Atara Schultz, MD
Endocrinology, Diabetes & Metabolism · Teaneck, NJNPI 1912112731
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $331,902 of the $357,172 with a category attached, or 92.9%. 7 manufacturers reported payments, led by Lilly USA, LLC at 53.5% of the total. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 452 payments — averaging $790.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$191K
- Novo Nordisk$166K
- Tandem Diabetes Care, Inc.$500
- Medtronic$38
- Insulet Corporation$35
- Sanofi-aventis U.S. LLC$28
- plus $15 from 1 others
What the payments were for
- Consulting fees$1,4000%
- Speaking & faculty fees$331,90293%
- Travel & lodging$17,9795%
- Food & beverage$5,8462%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 298 | $191,051 |
| Novo Nordisk | 145 | $165,504 |
| Tandem Diabetes Care, Inc. | 2 | $500 |
| Medtronic(2 entities) | 2 | $38 |
| Insulet Corporation | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Valeritas, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$116,049
- RYBELSUS$80,996
- Ozempic$75,604
- Tresiba$5,568
- t:slim X2 insulin pump$500
How this compares
$357,172 in reported general payments places this provider in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 464 | $592,974 |
| OzempicSemaglutide | 316 | $592,282 |
| TrulicityDulaglutide | 328 | $542,436 |
| MounjaroTirzepatide | 253 | $390,416 |
| FarxigaDapagliflozin Propanediol | 137 | $180,535 |
| Humalog Kwikpen U-200Insulin Lispro | 36 | $110,027 |
| Tresiba Flextouch U-200Insulin Degludec | 81 | $108,111 |
| JanuviaSitagliptin Phosphate | 79 | $95,174 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $92,492 |
| RybelsusSemaglutide | 37 | $70,054 |
| Tresiba Flextouch U-100Insulin Degludec | 94 | $65,719 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 47 | $59,920 |
| Bydureon BciseExenatide Microspheres | 37 | $48,421 |
| Humalog Kwikpen U-100Insulin Lispro | 114 | $40,987 |
| TradjentaLinagliptin | 30 | $35,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $191,051 | $955,242656 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $165,504 | $668,788364 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Teaneck
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
- Matthew CorcoranEgg Harbor Township$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.